Neuro-Oncology Reviews

Volume 24 Number 11
15 June 2022

Home > Publications > Neuro-Oncology Reviews > Volume 24, Year 2022 > Number 11, 15 June

Shah DS, Sanan A, Morell AA, Eichberg DG, Shah AH, Luther E, Lu VM, Elarjani T, Higgins DMO, Patel NV, Jagid JR, Ivan ME, Komotar RJ.
Traumatic brain injury and subsequent brain tumor development: a systematic review of the literature.
Neurosurg Rev. 2022 Jun 1→. doi: 10.1007/s10143-022-01819-y→. PMID: 35641842→. Review˰ ˍ

Shah HA, Mishra A, Gouzoulis MJ, Ben-Shalom N, D'Amico RS.
Analysis of factors leading to early termination in glioblastoma-related clinical trials.
J Neurooncol. 2022 Jun 1:1–7→. doi: 10.1007/s11060-022-04039-y→. PMID: 35648307→. Review. ˍ

Zhang J, Siller-Farfán JA.
Current and future perspectives of chimeric antigen receptors against glioblastoma.
Immunother Adv. 2022 Jun 1;2(1):ltac014→. doi: 10.1093/immadv/ltac014→. PMID: 36284838→. Review. ˍ

Kang H, Lee H, Kim D, Kim B, Kang J, Kim HY, Youn H, Youn B.
Targeting Glioblastoma Stem Cells to Overcome Chemoresistance: An Overview of Current Therapeutic Strategies.
Biomedicines. 2022 Jun 2;10(6):1308→. doi: 10.3390/biomedicines10061308→. PMID: 35740330→. Review. ˍ

Dutra JAP, Luiz MT, Tavares Junior AG, Di Filippo LD, Carvalho SG, Chorilli M.
Temozolomide: an Overview of Biological Properties, Drug Delivery Nanosystems, and Analytical Methods.
Curr Pharm Des. 2022 Jun 3→. doi: 10.2174/1381612828666220603152918→. PMID: 35658888→. Review˰ ˍ

Foss-Skiftesvik J, Stoltze UK.
Genetic predisposition to central nervous system tumors in children - what the neurosurgeon should know.
Acta Neurochir (Wien). 2022 Jun 3→. doi: 10.1007/s00701-022-05258-y→. PMID: 35660974→. Review˰ ˍ

Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ.
Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.
Br J Cancer. 2022 Jun 4→. doi: 10.1038/s41416-022-01864-w→. PMID: 35662275→. Review˰ ˍ

Waqar M, Roncaroli F, Lehrer EJ, Palmer JD, Villanueva-Meyer J, Braunstein S, Hall E, Aznar M, De Witt Hamer PC, D'Urso PI, Trifiletti D, Quiñones-Hinojosa A, Wesseling P, Bors GR.
Rapid early progression (REP) of glioblastoma is an independent negative prognostic factor: Results from a systematic review and meta-analysis.
Neurooncol Adv. 2022 Jun 4;4(1):vdac075→. doi: 10.1093/noajnl/vdac075→. PMID: 35769410→. Review, Meta-analysis. ˍ

Wyss J, Frank NA, Soleman J, Scheinemann K.
Novel Pharmacological Treatment Options in Pediatric Glioblastoma-A Systematic Review.
Cancers (Basel). 2022 Jun 6;14(11):2814→. doi: 10.3390/cancers14112814→. PMID: 35681794→. Review. ˍ

Singer L, Kumthekar P.
Editorial commentary: Society for Neuro-Oncology 2021 Annual Meeting updates on primary central nervous system tumors.
Chin Clin Oncol. 2022 Jun [7];11(3):18→. doi: 10.21037/cco-22-2→. PMID: 35818853→. Editorial. ˍ

*

Swildens KX, Sillevis Smitt PAE, van den Bent MJ, French PJ, Geurts M.
The effect of dexamethasone on the microenvironment and efficacy of checkpoint inhibitors in glioblastoma: a systematic review.
Neurooncol Adv. 2022 Jun 7;4(1):vdac087→. doi: 10.1093/noajnl/vdac087→. PMID: 35990704→. Review. ˍ

Shoaf ML, Desjardins A.
Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Neurotherapeutics. 2022 Jun 8→. doi: 10.1007/s13311-022-01256-1→. PMID: 35674873→. Review˰ ˍ

Alamer OB, Jimenez AE, Azad TD, Bettegowda C, Mukherjee D.
H3K27M-Altered Diffuse Midline Gliomas Among Adult Patients: A Systematic Review of Clinical Features and Survival Analysis.
World Neurosurg. 2022 Jun 10:S1878-8750(22)00803-8→. doi: 10.1016/j.wneu.2022.06.020→. PMID: 35697228→. Review˰ ˍ

Lafay-Cousin L, Baroni L, Ramaswamy V, Bouffet E.
How do we approach the management of medulloblastoma in young children?
Pediatr Blood Cancer. 2022 Jun 10:e29838→. doi: 10.1002/pbc.29838→. PMID: 35686728→. Review˰ ˍ

Kreatsoulas D, Bolyard C, Wu BX, Cam H, Giglio P, Li Z.
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
J Hematol Oncol. 2022 Jun 11;15(1):80→. doi: 10.1186/s13045-022-01298-0→. PMID: 35690784→. Review. ˍ

Kutuk T, Tolakanahalli R, McAllister NC, Hall MD, Tom MC, Rubens M, Appel H, Gutierrez AN, Odia Y, Mohler A, Ahluwalia MS, Mehta MP, Kotecha R.
Pulsed-Reduced Dose Rate (PRDR) Radiotherapy for Recurrent Primary Central Nervous System Malignancies: Dosimetric and Clinical Results.
Cancers (Basel). 2022 Jun 15;14(12):2946→. doi: 10.3390/cancers14122946→. PMID: 35740612→. Observational study, Review. ˍ

Shah AH, Heiss JD.
Neurosurgical Clinical Trials for Glioblastoma: Current and Future Directions.
Brain Sci. 2022 Jun 15;12(6):787→. doi: 10.3390/brainsci12060787→. PMID: 35741672→. Review. ˍ